

Kelyniam Global, Inc.

97 River Road
Canton, Ct 06019

Telephone 1 (800) 280-8192

Kelyniam.com
info@Kelyniam.com

Quarterly Report

For the period ending September 30, 2024 (the “Reporting Period”)

Outstanding Shares

The number of shares outstanding of our Common Stock was:

30,698,145 as of 9/30/2024 (*Current Reporting Period Date or More Recent Date*)

29,923,145 as of 12/31/2023 (*Most Recent Completed Fiscal Year End*)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company’s shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

The Company's name is Kelyniam Global, Inc.

From its inception in 2005 through October 2007, the corporation was named Ketner Global Investments, Inc.

Current State and Date of Incorporation or Registration: Nevada, 12/30/2005
Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years: N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception: N/A

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: N/A

Address of the issuer's principal executive office:

97 River Road
Canton, Ct 06019

Address of the issuer's principal place of business:

X Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Transfer Online
Phone: (503) 227-2950
Email: www.transferonline.com
Address: 512 SE Salmon St.
Portland, OR 97214

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol: KLYG
Exact title and class of securities outstanding: Common – Class A

CUSIP:	488359100		
Par or stated value:	.001		
Total shares authorized:	60,000,000	<u>as of date:</u>	09/30/2024
Total shares outstanding:	30,698,145	<u>as of date:</u>	09/30/2024
Total number of shareholders of record:	406	<u>as of date:</u>	09/30/2024

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol: N/A

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The company has a single class of common stock. The common equity, as governed under Nevada law is entitled to vote and participate in dividends and liquidation rights in accordance with the pro rata share of each share issued and outstanding.

The Company does not have shares with super voting rights, preemptions or other rights than class A common. The Board of Kelyniam believes in transparent and participatory governance in its corporate actions and, as such, has continued to adhere to all corporate issuances of securities using only class A common shares.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Not applicable as the Company has not issued preferred stock

3. Describe any other material rights of common or preferred stockholders.

Not applicable as the Company has a single class of common stock with no enumerated or special voting rights privileges.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

There have been no material modifications to the rights of holders of the company's securities during this or any other reporting period.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date 12/31/2021 Common: 28,993,145 Preferred: -0-			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>5/31/2022</u>	<u>New Issuance</u>	<u>150,000</u>	<u>Class A</u>	<u>.09</u>	<u>No</u>	<u>Laura Reed</u>	<u>Sign on bonus</u>	<u>Restricted</u>	<u>144</u>
<u>5/31/2022</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.09</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>5/31/2022</u>	<u>New Issuance</u>	<u>600,000</u>	<u>Class A</u>	<u>.09</u>	<u>No</u>	<u>Terrance Kurtenbach</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>6/2/2022</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Class A</u>	<u>.03</u>	<u>No</u>	<u>Mark Smith</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>6/2/2022</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Class A</u>	<u>.03</u>	<u>No</u>	<u>Chris Breault</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>8/30/2022</u>	<u>New Issuance</u>	<u>480,000</u>	<u>Class A</u>	<u>.03</u>	<u>No</u>	<u>Mark V Smith</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>8/30/2022</u>	<u>New Issuance</u>	<u>450,000</u>	<u>Class A</u>	<u>.03</u>	<u>No</u>	<u>Chris Breault</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Thomas McDonald</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>

<u>1/6/2023</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Terrance Kurtenbach</u>	<u>Board Svcs</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>20,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Deborah Chasse</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>25,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Faith DiFronzo</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>25,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Basiru Sumbundu</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>1/6/2023</u>	<u>New Issuance</u>	<u>10,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Diane Bjella</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>3/16/2023</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Jason Mayfield</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>9/12/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>LGL, LLC (Lisette Grunwell)</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>9/12/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>9/12/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Mark V Smith</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>9/12/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Ross Bjella</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>9/12/2023</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.1</u>	<u>No</u>	<u>Terrance Kurtenbach</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>2/08/2024</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Class A</u>	<u>.06</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>
<u>6/04/2024</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Class A</u>	<u>.06</u>	<u>No</u>	<u>Mark V Smith</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>7/25/2024</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.12</u>	<u>No</u>	<u>Ross Bjella</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>7/25/2024</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.12</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>7/25/2024</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.12</u>	<u>No</u>	<u>LGL LLC (Lisette Grunwell)</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>7/25/2024</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.12</u>	<u>No</u>	<u>Terrance Kurtenbach</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>7/25/2024</u>	<u>New Issuance</u>	<u>75,000</u>	<u>Class A</u>	<u>.12</u>	<u>No</u>	<u>WatersEdge LLC (Jonathan Thiel)</u>	<u>Board Svce</u>	<u>Restricted</u>	<u>144</u>
<u>8/26/2024</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Class A</u>	<u>.07</u>	<u>No</u>	<u>Desiree Webb</u>	<u>Compensation</u>	<u>Restricted</u>	<u>144</u>

Shares Outstanding on Date of This Report:	
<u>Ending</u>	<u>Balance</u>
<u>Ending Balance:</u>	
Date 09/30/2024	Common: 30,698,145

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes - N/A

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: X Yes: (If yes, you must complete the table below)

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company specializing in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures.

Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient's computed tomography (CT) data, the Company's 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. The Company's emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours.

The Company distributes its products throughout the United States via independent distributors and sales representatives promoting the product directly to neurosurgeons who have discretionary authority to purchase the product with superior fit and medical qualities. The ultimate customer is the hospital where the surgery is executed, and the hospital remains the buyer of record. As such, the Company incurs very few bad debts and revenue, when recognized, is ultimately collected.

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Cranial implants manufactured using Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology.



5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company leases 6,000 sq feet of facilities located in a US FDA inspected manufacturing facility in Canton, Ct. The plant is an end-to-end facility including the Cad-cam design capabilities and advanced additive manufacturing processes using 3-d printing. The end-to-end facility provides for control of the process resulting in superior capabilities for turn around times on delivery of implants to neurology departments at hospitals.

The real estate lease is in effect through December 31, 2027 with options to renew until 2032. Monthly lease payments are \$2,667 currently through December 31, 2023. Beginning 1/1/2024, lease payments will be \$2,800 monthly until December 31, 2027. Beginning 1/1/2028 lease payments will increase to \$2,830 monthly.

The Company also maintains secondary Executive Offices in Milwaukee, WI. The facilities are shared with other technology-oriented companies. The Company is not a party to a lease and the facilities are currently provided to the Company at no cost.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Ross Bjella*</u>	<u>CEO</u>	<u>Whitefish Bay, WI</u>	<u>2,167,500</u>	<u>Class A Common</u>	<u>7.3</u>	
<u>Lisette Grunwell</u>	<u>Director</u>	<u>Old Lyme, CT</u>	<u>150,000</u>	<u>Class A Common</u>	<u>0.49</u>	
<u>Jonathan Thiel dba WatersEdge</u>	<u>Director</u>	<u>Oconomowoc, WI</u>	<u>75,000</u>	<u>Class A Common</u>	<u>.24</u>	
<u>Stan Solomonson</u>	<u>5% Owner</u>	<u>Santa Rosa, CA</u>	<u>2,200,000</u>	<u>Class A Common</u>	<u>7.17</u>	
<u>Terrance Kurtenbach</u>	<u>CFO</u>	<u>Germantown, WI</u>	<u>2,225,000</u>	<u>Class A Common</u>	<u>7.25</u>	
<u>Patrick McMurchy</u>	<u>5% Owner</u>	<u>Tulsa, Ok</u>	<u>1,620,000</u>	<u>Class A Common</u>	<u>5.28</u>	
<u>Desiree Webb</u>	<u>Director</u>	<u>Boca Raton, FL</u>	<u>475,000</u>	<u>Class A Common</u>	<u>1.55</u>	
<u>Mark V Smith*</u>	<u>5% Owner</u>	<u>Pewaukee, WI</u>	<u>2,957,500</u> <u>0</u>	<u>Class A Common</u>	<u>9.63</u>	

*Includes shares beneficially owned by spouse

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.
Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Kevin Timken

Firm: Michael Best & Friedrich LLP
Address 1: 170 South Main St
Suite 1000
Salt Lake City, UT 84101

Phone: (801) 924.4124
Email: KCTimken@MichaelBest.com

Accountant or Auditor

Name: Ryan LaQuerre
Firm: LaQuerre Audi
Address 1: 106 East St
Plainville, CT 06062

Phone: (860) 747.4559
Email: info@laqcpa.com

Investor Relations – N/A

Other Service Providers N/A

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Terrance Kurtenbach
Title: Chief Financial Officer
Relationship to Issuer: Corporate Officer

B. The following financial statements were prepared in accordance with:

IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Terrance Kurtenbach
Title: CFO
Relationship to Issuer: Officer

Describe the qualifications of the person or persons who prepared the financial statements:⁵ Licensed CPA (ret.) and former Big 4 partner for 26 years

⁵ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Ross Bjella, certify that:

1. I have reviewed this Disclosure Statement for Kelyniam Global, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/10/2024

Chief Executive Officer:



/s/ Ross Bjella, CEO

Principal Financial Officer:

I, Terrance Kurtenbach certify that:

1. I have reviewed this Disclosure Statement for Kelyniam Global, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

11/10/2024

A handwritten signature in black ink, appearing to read 'T. Kurtenbach', written in a cursive style.

/s/ Terrance Kurtenbach, CFO

(Digital Signatures should appear as "/s/ [OFFICER NAME]")